Of particular interest, when Bowling and Wang et al. treated Myc-driven triple-negative breast cancer cells with the spliceosome targeted therapy H3B-8800, or directly degraded the splicing factor SF3B1, they saw increased endogenous dsRNA production leading to inflammatory cell death through antiviral pathways (122). This evidence concerns the gene MYC and triple-negative breast carcinoma.